These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3488197)

  • 21. Upper respiratory tract infections. Ecological and therapeutic aspects of beta-lactamase production with special reference to Branhamella catarrhalis.
    Eliasson I; Kamme C
    Drugs; 1986; 31 Suppl 3():116-21. PubMed ID: 3488190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A membrane-bound precursor beta-lactamase in strains of Moraxella catarrhalis and Moraxella nonliquefaciens that produce periplasmic BRO-1 and BRO-2 beta-lactamases.
    Steingrube VA; Wallace RJ; Beaulieu D
    J Antimicrob Chemother; 1993 Feb; 31(2):237-44. PubMed ID: 8463169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of immunoglobulin A1 protease production by Branhamella catarrhalis.
    McLeod DT; Croughan MJ; Ahmad F; Brettle RP; Calder MA
    Infect Immun; 1986 May; 52(2):631-2. PubMed ID: 3516884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct and indirect pathogenicity of Branhamella catarrhalis.
    Brook I
    Drugs; 1986; 31 Suppl 3():97-102. PubMed ID: 3488202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isoelectric focusing of beta-lactamases in Mycobacterium fortuitum. Association of a single enzyme pattern with cefoxitin resistance.
    Wallace RJ; Nash DR; Udou T; Steingrube VA; Steele LC; Swenson JM; Silcox VA
    Am Rev Respir Dis; 1985 Nov; 132(5):1093-7. PubMed ID: 3877482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid identification of metallo- and serine beta-lactamases.
    Payne DJ; Cramp R; Bateson JH; Neale J; Knowles D
    Antimicrob Agents Chemother; 1994 May; 38(5):991-6. PubMed ID: 8067782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Isolation of Branhamella catarrhalis from sputum and clinical features of bronchopulmonary infection due to Branhamella catarrhalis].
    Kinoshita A; Mukae H; Takase T; Ishino T; Kohno S; Kanda T; Yamaguchi K; Hirota M; Hara K
    Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Jun; 28(6):875-81. PubMed ID: 2120499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute otitis media in Sweden. Role of Branhamella catarrhalis and the rationale for choice of antimicrobial therapy.
    Lundgren K; Ingvarsson L
    Drugs; 1986; 31 Suppl 3():125-31. PubMed ID: 3488192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. beta-Lactam resistance and beta-lactamase isoforms of Moraxella catarrhalis isolates in Taiwan.
    Fung CP; Lee SC; Liu PY; Jang TN; Wong FD; Kuo BI; Liu CY; Liu YC
    J Formos Med Assoc; 1998 Jul; 97(7):453-7. PubMed ID: 9700241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of cell-bound papain-soluble beta-lactamases in BRO-1 and BRO-2 producing strains of Moraxella (Branhamella) catarrhalis and Moraxella nonliquefaciens.
    Eliasson I; Kamme C; Vang M; Waley SG
    Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):313-21. PubMed ID: 1396750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Branhamella catarrhalis as a lower respiratory tract pathogen in patients with chronic lung disease.
    Nicotra B; Rivera M; Luman JI; Wallace RJ
    Arch Intern Med; 1986 May; 146(5):890-3. PubMed ID: 3963981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fimbriation, hemagglutination and adherence properties of fresh clinical isolates of Branhamella catarrhalis.
    Ahmed K; Rikitomi N; Matsumoto K
    Microbiol Immunol; 1992; 36(10):1009-17. PubMed ID: 1362238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The incidence and antibiotic susceptibility of Branhamella catarrhalis in respiratory infections.
    Calder MA; Croughan MJ; McLeod DT; Ahmad F
    Drugs; 1986; 31 Suppl 3():11-6. PubMed ID: 3488189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Otitis media caused by beta-lactamase-producing Branhamella (Neisseria) catarrhalis.
    Lee WS; Fordham T; Alban J
    J Clin Microbiol; 1981 Jan; 13(1):222-3. PubMed ID: 6970205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the beta-lactamases of Branhamella catarrhalis by clavulanic acid and other inhibitors.
    Farmer T; Reading C
    Drugs; 1986; 31 Suppl 3():70-8. PubMed ID: 3488199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Branhamella (Moraxella) catarrhalis--a clinically relevant pathogen of bronchopulmonary diseases?].
    Radzuweit S; Kalich R
    Z Erkr Atmungsorgane; 1991; 177(1-2):82-7. PubMed ID: 1808857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. beta-Lactamase activity in sputum and indirect pathogenicity.
    Watanabe A; Oizumi K; Motomiya M
    Sci Rep Res Inst Tohoku Univ Med; 1991 Dec; 38(2-4):83-9. PubMed ID: 1843051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections.
    Slevin NJ; Aitken J; Thornley PE
    Lancet; 1984 Apr; 1(8380):782-3. PubMed ID: 6143094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isoelectric focusing patterns of beta-lactamases in the rapidly growing mycobacteria.
    Zhang Y; Wallace RJ; Steingrube VA; Brown BA; Nash R; Silcox A; Tsukamura M
    Tuber Lung Dis; 1992 Dec; 73(6):337-44. PubMed ID: 1292713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Branhamella catarrhalis as an indirect pathogen.
    Wardle JK
    Drugs; 1986; 31 Suppl 3():93-6. PubMed ID: 3732085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.